Prothena | PRTA - Debt


Prothena reported $9.08M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Exelixis USD 176.46M 3.38M Sep/2025
Immunic USD 0 0 Jun/2024
Incyte USD 40.41M 855K Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Prothena USD 9.08M 699K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xoma USD 120.79M 3.27M Jun/2024